THE INVESTOR

메뉴열기
March 28, 2024

[EQUITIES] ‘Samsung C&T’s stock price decline excessive’

PUBLISHED : July 16, 2018 - 11:37

UPDATED : July 16, 2018 - 11:57

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • sms

[THE INVESTOR] Samsung C&T’s recent stock price fall has been disproportionate, said Kyobo Securities on July 16, maintaining a “buy” recommendation and 180,000 won (US$159.40) target price.




Although uncertainties still remain over supervisory review of its subsidiary Samsung BioLogics’ audit, it is very unlikely that it could lead to extreme situations such as delisting, and even with a worst-case scenario, stock price under 130,000 won is excessive, said analyst Baek Gwang-je. 

Its revenue in the third quarter will gain 3.8 percent on-year to 7.7 trillion won and operating profit 13.3 percent to 289 billion won, as profits across sectors, from construction and trade to fashion and leisure will improve, added the analyst. 

By Hwang You-mee (glamazon@heraldcorp.com)

  • 페이스북
  • sms
최상단으로
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.